Polymorphism in Ecto-Nucleotide Pyrophosphatase/Phosphodiesterase 1 Gene (ENPP1/PC-1) and Early Development of Advanced Diabetic Nephropathy in Type 1 Diabetes

  1. Luis H. Canani,
  2. Daniel P.K. Ng,
  3. Adam Smiles,
  4. John J. Rogus,
  5. James H. Warram and
  6. Andrzej S. Krolewski
  1. From the Research Division, Joslin Diabetes Center, and the Department of Medicine, Harvard Medical School, Boston, Massachusetts

    Abstract

    A polymorphism in the ecto-nucleotide pyrophosphatase/phosphodiesterase 1 gene (ENPP1) (previously known as PC-1), resulting in an amino acid change from lysine to glutamine at codon 121 (K121Q), is associated with insulin resistance. A small follow-up study of patients with type 1 diabetes and proteinuria found that renal function declines more rapidly in carriers of the Q variant than in noncarriers. To examine this finding further, we conducted a large case-control study and a family-based study. Genomic DNA was obtained from 659 patients: 307 with normal urinary albumin excretion despite diabetes duration of >15 years (control subjects) and 352 with advanced diabetic nephropathy, of whom 200 had persistent proteinuria and 152 had end-stage renal disease (ESRD). Individuals were genotyped for Q and K variants using a previously described protocol. The frequency of Q variant carriers was 21.5% in control subjects, 31.5% in subjects with proteinuria, and 32.2% in subjects with ESRD (P = 0.012). In a stratified analysis according to duration of diabetes, the risk of early-onset ESRD for carriers of the Q variant was 2.3 times that for noncarriers (95% CI, 1.2–4.6). The Q variant was not associated with late-onset ESRD. Similar findings were obtained in a family-based study. We conclude that carriers of the Q variant of ENPP1 are at increased risk for developing ESRD early in the course of type 1 diabetes.

    Footnotes

    • Address correspondence and reprint requests to Andrzej S. Krolewski, Section on Genetics and Epidemiology, Research Division, Joslin Diabetes Center, One Joslin Place, Boston, MA 02215. E-mail: andrzej.krolewski{at}joslin.harvard.edu.

      Received for publication 31 July 2001 and accepted in revised form 4 January 2002.

      ACR, albumin/creatinine ratio; ESRD, end-stage renal disease; GFR, glomerular filtration rate; IRS, insulin receptor substrate; TDT, transmission disequilibrium test.

    « Previous | Next Article »Table of Contents